Country: Canada
Language: English
Source: Health Canada
IRBESARTAN
SIVEM PHARMACEUTICALS ULC
C09CA04
IRBESARTAN
300MG
TABLET
IRBESARTAN 300MG
ORAL
100/500
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0131700003; AHFS:
APPROVED
2012-05-25
_IRBESARTAN _ _Page 1 of 37_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR IRBESARTAN Irbesartan tablets Tablets, 75 mg, 150 mg and 300 mg, Oral USP Angiotensin II AT 1 Receptor Blocker Sivem Pharmaceuticals ULC 4705 Dobrin Street Saint-Laurent, Quebec, Canada H4R 2P7 www.sivem.ca Date of Initial Authorization MAY 25, 2012 Date of revision JAN 02, 2024 Submission Control No.: 281898 _IRBESARTAN _ _Page 2 of 37_ _ _ RECENT MAJOR LABEL CHANGES 7. WARNINGS AND PRECAUTIONS 01/2024 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES………………………………………………………………………….…...............2 TABLES OF CONTENTS………………...……………………………………………………………………….…...............2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ......................................................... 5 4.4 Administration .......................................................................................................... 6 4.5 Missed Dose ............................................... Read the complete document